Investigational New Drugs

, Volume 31, Issue 4, pp 974–985 | Cite as

A phase I dose-escalation study of intravenous panobinostat in patients with lymphoma and solid tumors

  • Sunil Sharma
  • Joachim Beck
  • Monica Mita
  • Sofia Paul
  • Margaret M. Woo
  • Margaret Squier
  • Brian Gadbaw
  • H. Miles Prince
PHASE I STUDIES

Summary

Purpose Panobinostat, a pan-deacetylase inhibitor, is a promising anti-cancer agent that increases acetylation of proteins associated with growth and survival pathways of malignant cells. The primary objective of this phase I dose-escalation study was to determine the maximum tolerated dose (MTD) of intravenous (i.v.) panobinostat administered on different dosing schedules in patients with advanced solid tumors or lymphoma. Secondary objective was to characterize safety and tolerability, pharmacokinetic profiles, and activities of the i.v. formulation. Methods i.v. panobinostat was administered at escalating doses on a daily (days 1–3 and 8–10 of a 21-day cycle; days 1–3 and 15–17 of a 28-day cycle) or weekly (days 1, 8, and 15 of a 28-day cycle; days 1 and 8 of a 21-day cycle) schedule, and safety and tolerability were monitored. Serial blood samples were collected following dosing for pharmacokinetic and pharmacodynamic analyses. Results The MTD for the daily administration schedule was 7.2 g/m2, whereas the MTD for the weekly schedule was 20.0 mg/m2. In addition to fatigue and cardiac arrhythmias, including prolonged QTcF, DLTs associated with the study drug were principally due to myelosuppressive effects. Maximum concentrations and bioavailability of i.v. panobinostat increased dose-proportionally across all doses evaluated. Conclusions Based on the results of this study and others, the i.v. formulation of panobinostat was well tolerated in many patients, but concerns remain regarding its potential suitability outside the study setting due to potential electrocardiogram abnormalities. Therefore, further development will focus on the panobinostat oral formulation.

Keywords

Panobinostat DAC DACi Cancer 

Supplementary material

10637_2013_9930_MOESM1_ESM.docx (16 kb)
ESM 1(DOCX 16 kb)

References

  1. 1.
    Choudhary C, Kumar C, Gnad F, Nielsen ML, Rehman M, Walther TC, Olsen JV, Mann M (2009) Lysine acetylation targets protein complexes and co-regulates major cellular functions. Science 325:834–840PubMedCrossRefGoogle Scholar
  2. 2.
    Bolden JE, Peart MJ, Johnstone RW (2006) Anticancer activities of histone deacetylase inhibitors. Nat Rev Drug Discov 5:769–784PubMedCrossRefGoogle Scholar
  3. 3.
    Minucci S, Pelicci PG (2006) Histone deacetylase inhibitors and the promise of epigenetic (and more) treatments for cancer. Nat Rev Cancer 6:38–51PubMedCrossRefGoogle Scholar
  4. 4.
    Vega RB, Matsuda K, Oh J, Barbosa AC, Yang X, Meadows E, McAnally J, Pomajzl C, Shelton JM, Richardson JA, Karsenty G, Olson EN (2004) Histone deacetylase 4 controls chondrocyte hypertrophy during skeletogenesis. Cell 119:555–566PubMedCrossRefGoogle Scholar
  5. 5.
    Qian DZ, Kato Y, Shabbeer S, Wei Y, Verheul HM, Salumbides B, Sanni T, Atadja P, Pili R (2006) Targeting tumor angiogenesis with histone deacetylase inhibitors: the hydroxamic acid derivative LBH589. Clin Cancer Res 12:634–642PubMedCrossRefGoogle Scholar
  6. 6.
    Lee YS, Lim KH, Guo X, Kawaguchi Y, Gao Y, Barrientos T, Ordentlich P, Wang XF, Counter CM, Yao TP (2008) The cytoplasmic deacetylase HDAC6 is required for efficient oncogenic tumorigenesis. Cancer Res 68:7561–7569PubMedCrossRefGoogle Scholar
  7. 7.
    Kornberg RD, Lorch Y (1999) Twenty-five years of the nucleosome, fundamental particle of the eukaryote chromosome. Cell 98:285–294PubMedCrossRefGoogle Scholar
  8. 8.
    Luger K (2006) Dynamic nucleosomes. Chromosome Res 14:5–16PubMedCrossRefGoogle Scholar
  9. 9.
    Johnstone RW (2002) Histone-deacetylase inhibitors: novel drugs for the treatment of cancer. Nat Rev Drug Discov 1:287–299PubMedCrossRefGoogle Scholar
  10. 10.
    Marks P, Rifkind RA, Richon VM, Breslow R, Miller T, Kelly WK (2001) Histone deacetylases and cancer: causes and therapies. Nat Rev Cancer 1:194–202PubMedCrossRefGoogle Scholar
  11. 11.
    Bali P, Pranpat M, Bradner J, Balasis M, Fiskus W, Guo F, Rocha K, Kumaraswamy S, Boyapalle S, Atadja P, Seto E, Bhalla K (2005) Inhibition of histone deacetylase 6 acetylates and disrupts the chaperone function of heat shock protein 90: a novel basis for antileukemia activity of histone deacetylase inhibitors. J Biol Chem 280:26729–26734PubMedCrossRefGoogle Scholar
  12. 12.
    Yang Y, Rao R, Shen J, Tang Y, Fiskus W, Nechtman J, Atadja P, Bhalla K (2008) Role of acetylation and extracellular location of heat shock protein 90alpha in tumor cell invasion. Cancer Res 68:4833–4842PubMedCrossRefGoogle Scholar
  13. 13.
    Gu W, Roeder RG (1997) Activation of p53 sequence-specific DNA binding by acetylation of the p53 C-terminal domain. Cell 90:595–606PubMedCrossRefGoogle Scholar
  14. 14.
    Qian DZ, Kachhap SK, Collis SJ, Verheul HM, Carducci MA, Atadja P, Pili R (2006) Class II histone deacetylases are associated with VHL-independent regulation of hypoxia-inducible factor 1 alpha. Cancer Res 66:8814–8821PubMedCrossRefGoogle Scholar
  15. 15.
    Verheul HM, Salumbides B, Van Erp K, Hammers H, Qian DZ, Sanni T, Atadja P, Pili R (2008) Combination strategy targeting the hypoxia inducible factor-1 alpha with mammalian target of rapamycin and histone deacetylase inhibitors. Clin Cancer Res 14:3589–3597PubMedCrossRefGoogle Scholar
  16. 16.
    Maiso P, Carvajal-Vergara X, Ocio EM, Lopez-Perez R, Mateo G, Gutierrez N, Atadja P, Pandiella A, San Miguel JF (2006) The histone deacetylase inhibitor LBH589 is a potent antimyeloma agent that overcomes drug resistance. Cancer Res 66:5781–5789PubMedCrossRefGoogle Scholar
  17. 17.
    Spencer A, Taylor K, Lonial S, Mateos MV, Jalaluddin M, Hazell K, Bourquelot PM, San Miguel JF (2009) Panobinostat plus lenalidomide and dexamethasone phase I trial in multiple myeloma (MM). J Clin Oncol 27 [abstract 8542]Google Scholar
  18. 18.
    DeAngelo DJ, Spencer A, Ottmann OG, Fischer T, Kindler T, Bhalla KN, Liu A, Parker K, Rupani H, Homji N, Ashton E, Jalaluddin M, Laird G, Scott JW, Prince HM (2009) Panobinostat has activity in treatment-refractory Hodgkin lymphoma. Haematologica 94:205 [abstract 0505]CrossRefGoogle Scholar
  19. 19.
    Lin R, Hu J, Paul S, Schindler J, Woo MM, Spence S, Hirawat S, Weber HA (2009) Characteristics of thrombocytopenia in patients treated with oral panobinostat (LBH589). Blood 114 [abstract 2740]Google Scholar
  20. 20.
    Giles F, Fischer T, Cortes J, Garcia-Manero G, Beck J, Ravandi F, Masson E, Rae P, Laird G, Sharma S, Kantarjian H, Dugan M, Albitar M, Bhalla K (2006) A phase I study of intravenous LBH589, a novel cinnamic hydroxamic acid analogue histone deacetylase inhibitor, in patients with refractory hematologic malignancies. Clin Cancer Res 12:4628–4635PubMedCrossRefGoogle Scholar
  21. 21.
    Simon R, Freidlin B, Rubinstein L, Arbuck SG, Collins J, Christian MC (1997) Accelerated titration designs for phase I clinical trials in oncology. J Natl Cancer Inst 89:1138–1147PubMedCrossRefGoogle Scholar
  22. 22.
    Neuenschwander B, Branson M, Gsponer T (2008) Critical aspects of the Bayesian approach to phase I cancer trials. Stat Med 27:2420–2439PubMedCrossRefGoogle Scholar
  23. 23.
    Cheson BD, Horning SJ, Coiffier B, Shipp MA, Fisher RI, Connors JM, Lister TA, Vose J, Grillo-Lopez A, Hagenbeek A, Cabanillas F, Klippensten D, Hiddemann W, Castellino R, Harris NL, Armitage JO, Carter W, Hoppe R, Canellos GP (1999) Report of an international workshop to standardize response criteria for non-Hodgkin’s lymphomas. NCI Sponsored International Working Group. J Clin Oncol 17:1244PubMedGoogle Scholar
  24. 24.
    Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, Dancey J, Arbuck S, Gwyther S, Mooney M, Rubinstein L, Shankar L, Dodd L, Kaplan R, Lacombe D, Verweij J (2009) New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 45:228–247PubMedCrossRefGoogle Scholar
  25. 25.
    Bunn PA Jr, Lamberg SI (1979) Report of the committee on staging and classification of cutaneous T-cell lymphomas. Cancer Treat Rep 63:725–728PubMedGoogle Scholar
  26. 26.
    Foss F (2003) Overview of cutaneous T-cell lymphoma: prognostic factors and novel therapeutic approaches. Leuk Lymphoma 44(Suppl 3):S55–S61PubMedCrossRefGoogle Scholar
  27. 27.
    Whittaker SJ, Marsden JR, Spittle M, Russell Jones R, British Association of Dermatologists, U.K., Cutaneous Lymphoma Group (2003) Joint British Association of Dermatologists and U.K. cutaneous lymphoma group guidelines for the management of primary cutaneous T-cell lymphomas. Br J Dermatol 149:1095–1107PubMedCrossRefGoogle Scholar
  28. 28.
    Hamberg P, Woo MM, Chen LC, Verweij J, Porro MG, Zhao L, Li W, van der Biessen D, Sharma S, Hengelage T, de Jonge M (2011) Effect of ketoconazole-mediated CYP3A4 inhibition on clinical pharmacokinetics of panobinostat (LBH589), an orally active histone deacetylase inhibitor. Cancer Chemother PharmacolGoogle Scholar
  29. 29.
    Ellis L, Pan Y, Smyth GK, George DJ, McCormack C, Williams-Truax R, Mita M, Beck J, Burris H, Ryan G, Atadja P, Butterfoss D, Dugan M, Culver K, Johnstone RW, Prince HM (2008) Histone deacetylase inhibitor panobinostat induces clinical responses with associated alterations in gene expression profiles in cutaneous T-cell lymphoma. Clin Cancer Res 14:4500–4510PubMedCrossRefGoogle Scholar
  30. 30.
    Babb J, Rogatko A, Zacks S (1998) Cancer phase I clinical trials: efficient dose escalation with overdose control. Stat Med 17:1103–1120PubMedCrossRefGoogle Scholar
  31. 31.
    Munster PN, Rubin EH, Van Belle S, Friedman E, Patterson JK, Van Dyck K, Li X, Comisar W, Chodakewitz JA, Wagner JA, Iwamoto M (2009) A single supratherapeutic dose of vorinostat does not prolong the QTc interval in patients with advanced cancer. Clin Cancer Res 15:7077–7084PubMedCrossRefGoogle Scholar
  32. 32.
    Piekarz RL, Frye AR, Wright JJ, Steinberg SM, Liewehr DJ, Rosing DR, Sachdev V, Fojo T, Bates SE (2006) Cardiac studies in patients treated with depsipeptide, FK228, in a phase II trial for T-cell lymphoma. Clin Cancer Res 12:3762–3773PubMedCrossRefGoogle Scholar
  33. 33.
    Wagner JM, Hackanson B, Lubbert M, Jung M (2010) Histone deacetylase (HDAC) inhibitors in recent clinical trials for cancer therapy. Clin Epigenetics 1:117–136PubMedCrossRefGoogle Scholar
  34. 34.
    Chiang CE (2004) Congenital and acquired long QT syndrome. Current concepts and management. Cardiol Rev 12:222–234PubMedCrossRefGoogle Scholar
  35. 35.
    Olsen EA, Kim YH, Kuzel TM, Pacheco TR, Foss FM, Parker S, Frankel SR, Chen C, Ricker JL, Arduino JM, Duvic M (2007) Phase IIb multicenter trial of vorinostat in patients with persistent, progressive, or treatment refractory cutaneous T-cell lymphoma. J Clin Oncol 25:3109–3115PubMedCrossRefGoogle Scholar
  36. 36.
    Rowinsky EK, de Bono J, Deangelo DJ, van Oosterom A, Morganroth J, Laird GH, Dugan M, Scott JW, Ottmann OG (2005) Cardiac monitoring in phase I trials of a novel histone deacetylase (HDAC) inhibitor LAQ824 in patients with advanced solid tumors and hematologic malignancies. J Clin Oncol 23 [abstract 3131]Google Scholar
  37. 37.
    Zhang L, Lebwohl D, Masson E, Laird G, Cooper MR, Prince HM (2008) Clinically relevant QTc prolongation is not associated with current dose schedules of LBH589 (panobinostat). J Clin Oncol 26:332–333, discussion 333–4PubMedCrossRefGoogle Scholar
  38. 38.
    Weber HA, Tai F, Paul S, Schindler J, Woo MM, Spence S, Marlowe J, Lin R (2009) QT interval measurements in patients with hematologic malignancies and solid tumors treated with oral panobinostat (LBH589). Blood 114 [abstract 3781]Google Scholar
  39. 39.
    Bates SE, Zhan Z, Steadman K, Obrzut T, Luchenko V, Frye R, Robey RW, Turner M, Gardner ER, Figg WD, Steinberg SM, Ling A, Fojo T, To KW, Piekarz RL (2010) Laboratory correlates for a phase II trial of romidepsin in cutaneous and peripheral T-cell lymphoma. Br J Haematol 148:256–267PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media New York 2013

Authors and Affiliations

  • Sunil Sharma
    • 1
  • Joachim Beck
    • 2
  • Monica Mita
    • 3
  • Sofia Paul
    • 4
  • Margaret M. Woo
    • 4
  • Margaret Squier
    • 4
  • Brian Gadbaw
    • 4
  • H. Miles Prince
    • 5
  1. 1.Huntsman Cancer InstituteUniversity of UtahSalt Lake CityUSA
  2. 2.University of MainzMainzGermany
  3. 3.Cedars-Sinai Medical CenterLos AngelesUSA
  4. 4.Novartis Pharmaceuticals CorporationEast HanoverUSA
  5. 5.Peter MacCallum Cancer Centre and The Sir Peter MacCallum Department of OncologyThe University of MelbourneMelbourneAustralia

Personalised recommendations